ʻO nā ʻike i ʻike ʻia he kiʻekiʻe loa ka COVID no ka poʻe ulaula, nā mea maʻi me nā comorbidities e like me ka hānō a i ʻole ka maʻi ʻāʻī, ka maʻi kanesa, ka maʻi maʻi maʻi maʻi, ka maʻi diabetes, ka puʻuwai congestive a i ʻole ka myocardial infarction, a me ka poʻe e lawe ana i nā corticosteroids.
"He mea koʻikoʻi ka ʻike i ka hopena o kēia pilikia," wahi a Medha Barbhaiya, MD, MPH, he rheumatologist ma HSS nāna i alakaʻi i ke aʻo ʻana. "No ka poʻe maʻi rheumatology, paʻakikī paha ka COVID lōʻihi no ka mea ua loaʻa i kēia mau maʻi nā pilikia olakino koʻikoʻi a pono e hoʻokolokolo hou."
Ua hōʻike ʻo Kauka Barbhaiya a me kāna mau hoa hana i kā lākou noiʻi, "Risk Factors for 'Long Haul' COVID-19 in Rheumatology Outpatients in New York City," ma ka hui makahiki ʻo American College of Rheumatology (ACR).
No ke aʻo ʻana, ua leka uila ka hui o Dr. Barbhaiya i nā noiʻi i 7,505 mau kāne a me nā wahine he 18 mau makahiki a ʻoi aku i mālama ʻia ma HSS no nā hoʻopiʻi rheumatologic ma waena o 2018 a me 2020. ua haʻi ʻia iā lākou e kahi mea mālama olakino ua loaʻa lākou i ka maʻi.
Ua wehewehe ka poʻe noiʻi i nā maʻi COVID-19 lōʻihi e like me ka poʻe me nā hōʻailona e mau ana i hoʻokahi mahina a ʻoi aku paha, ʻoiai ua manaʻo ʻia nā hihia i kaupalena ʻia me nā hōʻailona ma lalo o hoʻokahi mahina.
Ma waena o nā poʻe 2,572 i hoʻopau i ka noiʻi, kokoke i 56% o nā mea maʻi i hōʻike i ka loaʻa ʻana o COVID-19 i ʻōlelo ʻia ua mau ko lākou mau hōʻailona ma kahi o hoʻokahi mahina. ʻElua wale nō mea maʻi i loko o ke aʻo ʻana i loaʻa i kahi maʻi ma mua o ka fibromyalgia - kahi kūlana i hōʻailona ʻia e ka luhi, nā ʻeha ʻeha a me nā hōʻailona ʻē aʻe i pili pū me ka COVID lōʻihi - e hōʻike ana he liʻiliʻi ka overlap ma waena o nā maʻi ʻelua.
"ʻAʻole hōʻike kā mākou mau ʻike e kuhi hewa ʻia nā hōʻailona o ka fibromyalgia e like me ka lōʻihi o ka COVID i nā maʻi me nā maʻi rheumatic, ʻo ia kekahi mea i hāpai ʻia e like me ka hiki," wahi a Lisa A. Mandl, MD, MPH, he rheumatologist ma HSS a mea kākau kiʻekiʻe o ka haʻawina hou.
Hoʻolālā ka poʻe noiʻi HSS e hoʻohana i ka ʻikepili ma ke ʻano o ka loiloi longitudinal o nā mea maʻi rheumatology me COVID lōʻihi-haul e hoʻoholo ai inā pili nā hōʻailona lohi o ka maʻi i ko lākou kūlana rheumatologic. ʻO ka nānā mau ʻana o kēia mau maʻi e hāʻawi i ka ʻike koʻikoʻi i ka hopena lōʻihi o COVID-19 i nā maʻi me ka maʻi rheumatic.
He aha e lawe ʻia mai kēia ʻatikala:
- HSS researchers plan to use the data as part of a longitudinal analysis of rheumatology patients with long-haul COVID to determine if the lingering symptoms of the infection interfere with their rheumatologic conditions.
- Only two patients in the study had a previous diagnosis of fibromyalgia — a condition marked by fatigue, muscle aches and other symptoms that have been associated with long-haul COVID — suggesting that overlap between the two disorders is minimal.
- “Our findings do not suggest that symptoms of fibromyalgia are being misinterpreted as long haul COVID in patients with rheumatic diseases, which is something that has been raised as a possibility,”.
